Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis: Understanding the Mechanism and Mediators of Action
Sponsor: Center for Medicinal Cannabis Research
A PHASE3 clinical study on Early Psychosis, this trial is actively recruiting participants. The trial is conducted by Center for Medicinal Cannabis Research and has accumulated 9 data snapshots since 2022. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Unknown Status → Recruiting
-
Aug 2023 — Jun 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Sep 2021 — Aug 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Center for Medicinal Cannabis Research
- University of California, San Diego
For direct contact, visit the study record on ClinicalTrials.gov .